CDT.US CDT Equity Inc.

Healthcare Life Sciences Tools & Services USA Stocks
0.4004 USD
Close of Nov 13, 2026
0.3800 291,250
Market cap
USD 408K
P/E
-
P/B
0.00x
ROE
17.3%
Dividend yield
1,954.60%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is CDT.US undervalued?

Graham number

The Graham number of CDT Equity Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CDT Equity Inc. fundamental analysis

No fundamental analysis for CDT Equity Inc. yet.

CDT Equity Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CDT Equity Inc.

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I cli…

Full company profile